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A bs tr ac t
Background
The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding 
domain, which is the target of enzalutamide and abiraterone, but remains consti-
tutively active as a transcription factor. We hypothesized that detection of andro-
gen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells 
from men with advanced prostate cancer would be associated with resistance to 
enzalutamide and abiraterone.
Methods
We used a quantitative reverse-transcriptase–polymerase-chain-reaction assay to eval-
uate AR-V7 in circulating tumor cells from prospectively enrolled patients with 
metastatic castration-resistant prostate cancer who were initiating treatment with 
either enzalutamide or abiraterone. We examined associations between AR-V7 status 
(positive vs. negative) and prostate-specific antigen (PSA) response rates (the primary 
end point), freedom from PSA progression (PSA progression–free survival), clinical 
or radiographic progression–free survival, and overall survival.
Results
A total of 31 enzalutamide-treated patients and 31 abiraterone-treated patients were 
enrolled, of whom 39% and 19%, respectively, had detectable AR-V7 in circulating 
tumor cells. Among men receiving enzalutamide, AR-V7–positive patients had low-
er PSA response rates than AR-V7–negative patients (0% vs. 53%, P = 0.004) and 
shorter PSA progression–free survival (median, 1.4 months vs. 6.0 months; P<0.001), 
clinical or radiographic progression–free survival (median, 2.1 months vs. 6.1 months; 
P<0.001), and overall survival (median, 5.5 months vs. not reached; P = 0.002). Sim-
ilarly, among men receiving abiraterone, AR-V7–positive patients had lower PSA 
response rates than AR-V7–negative patients (0% vs. 68%, P = 0.004) and shorter PSA 
progression–free survival (median, 1.3 months vs. not reached; P<0.001), clinical or 
radiographic progression–free survival (median, 2.3 months vs. not reached; P<0.001), 
and overall survival (median, 10.6 months vs. not reached, P = 0.006). The association 
between AR-V7 detection and therapeutic resistance was maintained after adjustment 
for expression of full-length androgen receptor messenger RNA.
Conclusions
Detection of AR-V7 in circulating tumor cells from patients with castration-resis-
tant prostate cancer may be associated with resistance to enzalutamide and abiraterone. 
These findings require large-scale prospective validation. (Funded by the Prostate 
Cancer Foundation and others.)
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It is now accepted that castration-resistant prostate cancer is not androgen-independent and continues to rely on andro-
gen signaling.1 Owing to this new understanding, 
several drugs have recently emerged for the treat-
ment of castration-resistant prostate cancer; these 
agents either suppress the synthesis of extrago-
nadal androgens or target the androgen receptor 
directly.2 Enzalutamide is an inhibitor of andro-
gen-receptor signaling that exerts its activity by 
binding avidly to the ligand-binding domain of 
the androgen receptor, competing with and dis-
placing the natural ligands of this receptor (testos-
terone and dihydrotestosterone) while also inhib-
iting translocation of the androgen receptor into 
the nucleus and impairing transcriptional activa-
tion of androgen-responsive target genes.3,4 Abir-
aterone is an inhibitor of cytochrome P450 17A1 
(CYP17A1) that impairs androgen-receptor sig-
naling by depleting adrenal and intratumoral 
androgens.5,6 After studies showed improved 
survival with these drugs,7-9 both agents were ap-
proved by the Food and Drug Administration for 
the treatment of metastatic castration-resistant 
prostate cancer.
Although enzalutamide and abiraterone rep-
resent breakthroughs in the treatment of meta-
static castration-resistant prostate cancer, approxi-
mately 20 to 40% of patients have no response to 
these agents with respect to prostate-specific 
antigen (PSA) levels (i.e., they have primary re-
sistance).4,7-9 Among patients who initially have 
a response to enzalutamide or abiraterone, virtu-
ally all eventually acquire secondary resistance. 
One plausible explanation for the resistance to 
both agents may involve the presence of androgen-
receptor splice variants.10,11 These alternatively 
spliced variants encode a truncated androgen-
receptor protein that lacks the C-terminal li-
gand-binding domain but retains the transacti-
vating N-terminal domain.12,13 Although the 
resultant truncated proteins are unable to bind 
ligand, they are constitutively active as transcrip-
tion factors and capable of promoting activation 
of target genes.
Because enzalutamide exerts its antitumor ac-
tivity through its interaction with the ligand-bind-
ing domain of the androgen receptor, it would be 
expected that the presence of the protein encoded 
by the androgen-receptor variant (which lacks the 
ligand-binding domain) may be associated with 
enzalutamide resistance. Furthermore, this pro-
tein is ligand-independent and yet constitutively 
active, and its activity would not be expected to 
be inhibited by ligand-depleting agents such as 
abiraterone. Although these hypotheses are sup-
ported by preclinical studies,10,11,14,15 the clinical 
significance of androgen-receptor variants in pa-
tients receiving enzalutamide or abiraterone is 
unknown.
To investigate the clinical relevance of andro-
gen-receptor variants in castration-resistant pros-
tate cancer, we prospectively evaluated androgen-
receptor splice variant 7 messenger RNA (AR-V7) 
in circulating tumor cells from patients receiving 
enzalutamide or abiraterone. Although multiple 
androgen-receptor variants have been discovered, 
we focused on AR-V7 because it is the only 
known androgen-receptor variant encoding a 
functional protein product that is detectable in 
clinical specimens.13,16 We hypothesized that de-
tection of AR-V7 in circulating tumor cells may 
be associated with resistance to enzalutamide 




We prospectively enrolled men with metastatic 
castration-resistant prostate cancer who were be-
ginning standard-of-care treatment with enzalu-
tamide or abiraterone. Patients were required to 
have histologically confirmed prostate adenocar-
cinoma, progressive disease despite “castration lev-
els” of serum testosterone (<50 ng per deciliter 
[1.73 nmol per liter]) with continued androgen-
deprivation therapy, and documented metastases, 
as confirmed on computed tomography (CT) or 
bone scanning with technetium-99m–labeled 
methylene diphosphonate. Patients had to have 
three or more rising serum PSA values obtained 
2 or more weeks apart, with the last value being 
2.0 ng per milliliter or higher — criteria for PSA 
progression that are consistent with Prostate Can-
cer Clinical Trials Working Group 2 (PCWG2) 
guidelines.17 Patients were excluded if they planned 
to receive additional concurrent anticancer thera-
pies. Prior chemotherapy was permitted, as was 
previous treatment with the alternative agent di-
rected at the androgen receptor (i.e., prior abir-
aterone use in enzalutamide-treated patients and 
vice versa). All enrolled patients provided written 
informed consent.
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Study Design and Assessments
This was a prospective study evaluating the abil-
ity of baseline (pretreatment) AR-V7 status (posi-
tive vs. negative) in circulating tumor cells to pre-
dict a response or resistance to agents directed at 
the androgen receptor. The study was approved by 
the institutional review board at Johns Hopkins 
University. All the authors vouch for the complete-
ness and integrity of the data and for the fidelity 
of the study to the clinical protocol (available with 
the full text of this article at NEJM.org). Periph-
eral-blood samples, for analysis of circulating 
tumor cells, were obtained from eligible patients 
at three prespecified time points: baseline, the time 
of a clinical or biochemical response (if a response 
occurred), and the time of clinical or radiographic 
progression. In addition, patients were encouraged 
to undergo core-needle biopsies of metastatic tu-
mors at baseline and at the time of progression. 
Enzalutamide was given at a dose of 160 mg daily; 
abiraterone was given at a dose of 1000 mg daily, 
with prednisone at a dose of 5 mg twice daily.
The times of follow-up assessments were pro-
spectively defined: PSA measurements were ob-
tained every 1 to 2 months, and CT of the chest, 
abdomen, and pelvis and technetium-99m bone 
scanning were performed every 2 to 4 months. 
Therapy with enzalutamide or abiraterone was 
continued until PSA progression, clinical or radio-
graphic progression, or the occurrence of un-
manageable drug-related toxic effects. 
All the clinical investigators were unaware of 
the AR-V7 status of the participants. All the labo-
ratory investigators were unaware of clinical in-
formation when determining AR-V7 status. The 
study statisticians were the first to unblind the 
data, after at least 30 patients had been enrolled 
per cohort.
Analysis of Circulating Tumor Cells  
and Tumor Tissue 
Descriptions of the methods used for the capture 
of circulating tumor cells and of messenger RNA 
(mRNA) analysis for full-length androgen recep-
tor and AR-V7 are provided in the Supplementary 
Appendix, available at NEJM.org. Quantitative 
reverse-transcriptase–polymerase-chain-reaction 
(RT-PCR) assays were used for mRNA detection.
The analysis of AR-V7 in metastatic tumor tis-
sue is also described in the Supplementary Appen-
dix. RNA in situ hybridization assays were used.
Clinical Outcomes
The primary end point was the proportion of pa-
tients with a PSA response (≥50% decline in PSA 
level from baseline, maintained for ≥4 weeks) at 
any time after the initiation of therapy; the end 
point was assessed separately for enzalutamide-
treated patients and abiraterone-treated patients. 
The best PSA response (maximal percentage de-
crease in PSA level from baseline) for each pa-
tient was also determined.
Secondary end points were freedom from PSA 
progression (PSA progression–free survival), 
freedom from clinical or radiographic progres-
sion (clinical or radiographic progression–free 
survival), and overall survival. PSA progression 
was defined as an increase in the PSA level of 
25% or more above the nadir (and by ≥2 ng per 
milliliter), with confirmation 4 or more weeks 
later (PCWG2 criteria).17 Clinical or radiographic 
progression was defined as symptomatic pro-
gression (worsening disease-related symptoms 
or new cancer-related complications), radio-
graphic progression (≥20% increase in the sum 
of the diameters of soft-tissue target lesions on 
CT scanning [according to the Response Evalua-
tion Criteria in Solid Tumors18] or ≥2 new bone 
lesions on bone scanning), or death, whichever 
occurred first.17 Overall survival was defined as 
the time to death from any cause.
Statistical Analysis
Statistical analyses were performed separately in 
the enzalutamide and abiraterone cohorts. The 
sample size was determined on the basis of the 
primary end point of PSA response. We assumed 
that AR-V7 would be detectable from baseline 
samples of circulating tumor cells in 50% of 
enzalutamide-treated patients and 50% of abir-
aterone-treated patients. In both cohorts, we hy-
pothesized that PSA response rates would be 
10% or less in AR-V7–positive patients and 60% 
or more in AR-V7–negative patients.7,8 With this 
assumption, we calculated that a sample of 30 
patients per cohort would give the study 85% 
power to detect a difference of 50 percentage 
points in PSA response rates (i.e., a rate of 10% 
in AR-V7–positive men and 60% in AR-V7–nega-
tive men), with the use of a two-sided test at an 
alpha level of 0.10.
In each cohort, clinical outcomes were com-
pared between AR-V7–positive patients and AR-
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V7–negative patients. PSA response rates were 
compared with the use of Fisher’s exact test. 
Time-to-event outcomes (i.e., PSA progression–
free survival, clinical or radiographic progression–
free survival, and overall survival) were evaluated 
with the use of Kaplan–Meier methods, and sur-
vival-time differences were compared with the 
use of the log-rank test. Univariate and multi-
variable Cox regressions were used to assess the 
effect of AR-V7 status on the prediction of time-
to-event outcomes. Owing to the small sample 
size and the limited number of events, each multi-
variable model included only three variables 
(AR-V7 status, the level of expression of full-
length androgen receptor, and prior use of the 
alternative therapy directed at the androgen re-
ceptor), to prevent overfitting.
We also performed propensity-score–weight-
ed multivariable Cox analyses for PSA progres-
sion–free survival and clinical or radiographic 
progression–free survival, in which the propen-
sity score (the probability of being AR-V7–posi-
tive) was calculated from logistic regression 
with the use of variables including the Gleason 
score, the baseline PSA level, the number of 
prior hormonal treatments, the presence or ab-
sence of visceral metastases, the Eastern Coop-
erative Oncology Group (ECOG) score, prior use 
of abiraterone or enzalutamide, and the level of 
full-length androgen receptor. All tests were 
two-sided, and P values of 0.05 or less were con-
sidered to indicate statistical significance. Sta-
tistical analyses were performed with the use of 
R software, version 2.15.1.
R esult s
AR-V7 Detection in Circulating Tumor Cells
We first demonstrated our ability to detect AR-V7 
transcript in cells by looking for AR-V7 in normal 
human blood spiked with VCaP cells (Fig. S1A in 
the Supplementary Appendix), a prostate-cancer 
cell line known to express both full-length an-
drogen receptor and AR-V7.13 We then assayed 
the patient samples; examples of positive and 
negative detection of AR-V7 in blood samples 
from two patients are shown in Figure S1B in the 
Supplementary Appendix. After the validity of the 
assay was established (not shown), AR-V7 posi-
tivity was defined as detection of the AR-V7 tran-
script by means of a quantitative RT-PCR assay at 
36 or fewer PCR cycles, corresponding to detection 
of one or more copies of AR-V7 complementary 
DNA as determined by the relationship between 
cycle number and serial dilutions of prequantified 
AR-V7 (Fig. S2 in the Supplementary Appendix).
Patient Characteristics
From December 2012 through September 2013, 
we prospectively enrolled 62 patients with detect-
able circulating tumor cells, of whom 31 received 
enzalutamide and 31 received abiraterone (Table 
S1 in the Supplementary Appendix). A total of 35 
enzalutamide-treated men were screened to iden-
tify 31 with detectable circulating tumor cells 
(89% yield); 36 abiraterone-treated men were 
screened to identify 31 with detectable circulat-
ing tumor cells (86% yield). The 9 men with no 
detectable circulating tumor cells were excluded 
from further analysis. The median follow-up time 
was 5.4 months (range, 1.4 to 9.9) among enzalu-
tamide-treated patients and 4.6 months (range, 
0.9 to 8.2) among abiraterone-treated patients. A 
total of 39% of enzalutamide-treated patients (12 
of 31 patients) and 19% of abiraterone-treated 
patients (6 of 31 patients) had detectable AR-V7 
mRNA in baseline samples of circulating tumor 
cells. Among the 18 men with detectable AR-V7 
from the entire study cohort, the median ratio of 
AR-V7 to full-length androgen receptor mRNA 
was 21.0% (range, 1.8 to 208.0) (Fig. 1); detection 
of AR-V7 was associated with increased expres-
sion of full-length androgen receptor mRNA 
(P<0.001).
In the enzalutamide cohort, AR-V7–positive 
patients had higher levels of full-length andro-
gen receptor mRNA and PSA than did AR-V7–
negative patients and were more likely than 
AR-V7–negative patients to have an ECOG perfor-
mance-status score of 1 or 2 (scores range from 
0 to 5, with 0 indicating no symptoms and 
higher scores indicating increasing disability), 
visceral metastases, and six or more bone metas-
tases and to have had prior docetaxel treatment 
and prior abiraterone treatment (Table S1A in the 
Supplementary Appendix). A total of 55% of the 
patients who had previously received abiraterone 
(11 of 20 patients) had detectable AR-V7, as com-
pared with 9% of the patients who had not 
previously received the drug (1 of 11 patients). 
Table S2A in the Supplementary Appendix shows 
clinical outcomes separately for patients who had 
previously received abiraterone and those who 
had not previously received the drug.
The New England Journal of Medicine 
Downloaded from nejm.org on September 12, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 371;11 nejm.org september 11, 20141032
In the abiraterone cohort, AR-V7–positive pa-
tients had higher levels of full-length androgen 
receptor mRNA, PSA, and alkaline phosphatase, 
and a higher number of prior hormonal thera-
pies than did AR-V7–negative patients and were 
more likely than AR-V7–negative patients to have 
an ECOG performance-status score of 1 or 2 and 
prior enzalutamide treatment (Table S1B in the 
Supplementary Appendix). A total of 50% of 
patients who had previously received enzalu-
tamide (2 of 4 patients) had detectable AR-V7, as 
compared with 15% of patients who had not 
previously received the drug (4 of 27 patients). 
Table S2B in the Supplementary Appendix shows 
clinical outcomes separately for patients who 
had previously received enzalutamide and those 
who had not previously received the drug.
Primary End Point
The overall proportion of patients who had a PSA 
response while receiving enzalutamide was 32% 
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Figure 1. Transcript Levels of Full-Length Androgen Receptor mRNA and AR-V7 in Circulating Tumor Cells  
from Patients with Castration-Resistant Prostate Cancer.
Absolute transcript copy numbers of full-length androgen receptor messenger RNA (mRNA) and androgen-receptor 
splice variant 7 mRNA (AR-V7) detected in circulating tumor cells are shown for the 6 abiraterone-treated patients 
(Panel A) and the 12 enzalutamide-treated patients (Panel B) who were positive for AR-V7 at baseline (i.e., in pre-
treatment samples of circulating tumor cells). Ratios of AR-V7 to full-length androgen receptor mRNA are expressed 
as percentages. Levels of full-length androgen receptor mRNA are also shown for AR-V7–negative samples. Eight 
abiraterone-treated patients who were negative for full-length androgen receptor mRNA (not shown) were also neg-
ative for AR-V7. One enzalutamide-treated patient was negative for both full-length androgen receptor mRNA and 
AR-V7 (not shown).
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men). In the enzalutamide cohort, the PSA re-
sponse rate among AR-V7–positive patients was 
0% (95% CI, 0 to 26; 0 of 12 men), and the rate 
among AR-V7–negative patients was 53% (95% CI, 
29 to 76; 10 of 19 men; P = 0.004). The best PSA re-
sponses are shown in Figure 2A. In linear regres-
sion modeling, AR-V7 status remained predictive of 
PSA response after adjustment for the expression of 
full-length androgen receptor mRNA (P<0.001).
The overall proportion of patients who had a 
PSA response while receiving abiraterone was 55% 
(95% CI, 36 to 73; 17 of 31 men). In the abir-
aterone cohort, the PSA response rate among 
AR-V7–positive patients was 0% (95% CI, 0 to 46; 
0 of 6 men), and the rate among AR-V7–negative 
patients was 68% (95% CI, 46 to 85; 17 of 25 
men; P = 0.004). The best PSA responses are shown 
in Figure 2B. In linear regression modeling, AR-V7 
status remained predictive of PSA response after 
adjustment for the expression of full-length an-
drogen receptor mRNA (P = 0.02).
Secondary End Points
PSA Progression–free Survival
Among enzalutamide-treated patients, PSA pro-
gression–free survival was shorter among men 
with detectable AR-V7 at baseline than among 
those with undetectable AR-V7 (P<0.001 in a uni-
variate analysis) (Fig. 3A). In a multivariable Cox 
model adjusted for the expression of full-length 
androgen receptor mRNA and prior abiraterone 
use, the detection of AR-V7 remained indepen-
dently predictive of shorter PSA progression–free 
survival (hazard ratio for PSA progression, 3.1; 
95% CI, 1.0 to 9.2; P = 0.046); the level of full-
length androgen receptor mRNA was also pre-
dictive of shorter PSA progression–free survival 
(hazard ratio, 1.4; 95% CI, 1.0 to 1.9), but previ-
ous abiraterone use was not (hazard ratio, 2.5; 
95% CI, 0.4 to 14.5). Results of the propensity-
score–weighted multivariable model are shown 
in Table S3A in the Supplementary Appendix.
Among abiraterone-treated patients, PSA pro-
gression–free survival was shorter among men 
with detectable AR-V7 at baseline than among 
those with undetectable AR-V7 (P<0.001 in a 
univariate analysis) (Fig. 3B). In a multivariable 
Cox model adjusted for the expression of full-
length androgen receptor mRNA and prior 
enzalutamide use, the detection of AR-V7 was 
the only independent predictor of shorter PSA 
progression–free survival (hazard ratio for PSA 
progression, 15.7; 95% CI, 2.1 to 117.5; P = 0.007); 
neither the level of full-length androgen receptor 
mRNA (hazard ratio, 1.0; 95% CI, 0.8 to 1.2) nor 
previous enzalutamide use (hazard ratio, 0.9; 
95% CI, 0.1 to 5.2) was predictive. Results of the 
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Figure 2. Waterfall Plots of Best Prostate-Specific Antigen (PSA) Responses 
According to AR-V7 Status.
Panel A shows the 31 enzalutamide-treated patients, and Panel B the 31 
abiraterone-treated patients. The dotted line shows the threshold for defin-
ing a PSA response (≥50% reduction in PSA level from baseline). Asterisks 
indicate an increase of more than 100% in best PSA response. Daggers in-
dicate patients in the enzalutamide cohort who had previously received 
abir aterone and patients in the abiraterone cohort who had previously re-
ceived enzalutamide.
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are shown in Table S3C in the Supplementary 
Appendix.
Clinical or Radiographic Progression–free Survival
Among enzalutamide-treated patients, clinical or 
radiographic progression–free survival was short-
er among men with detectable AR-V7 at baseline 
than among those with undetectable AR-V7 
(P<0.001 in a univariate analysis) (Fig. 3C). In a 
multivariable Cox model adjusted for the expres-
sion of full-length androgen receptor mRNA and 
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Figure 3. Kaplan–Meier Analysis of PSA Progression–free Survival and Clinical or Radiographic Progression–free Survival According to 
AR-V7 Status.
The median PSA progression–free survival in enzalutamide-treated patients (Panel A) was 1.4 months (95% CI, 0.9 to not reached) in 
AR-V7–positive patients and 6.0 months (95% CI, 3.8 to not reached) in AR-V7–negative patients (hazard ratio for PSA progression with 
AR-V7 positivity, 7.4; 95% CI, 2.7 to 20.6; P<0.001 by the log-rank test). The median PSA progression–free survival in abiraterone-treated 
patients (Panel B) was 1.3 months (95% CI, 0.9 to not reached) in AR-V7–positive patients and more than 5.3 months (95% CI, 5.3 to 
not reached) in AR-V7–negative patients (hazard ratio for PSA progression with AR-V7 positivity, 16.1; 95% CI, 3.9 to 66.0; P<0.001 by 
the log-rank test). The median clinical or radiographic progression–free survival in enzalutamide-treated patients (Panel C) was 2.1 
months (95% CI, 2.0 to not reached) in AR-V7–positive patients and 6.1 months (95% CI, 4.7 to not reached) in AR-V7–negative pa-
tients (hazard ratio for clinical or radiographic progression with AR-V7 positivity, 8.5; 95% CI, 2.8 to 25.5; P<0.001 by the log-rank test). 
The median clinical or radiographic progression–free survival in abiraterone-treated patients (Panel D) was 2.3 months (95% CI, 1.4 to 
not reached) in AR-V7–positive patients and more than 6.3 months (95% CI, 6.3 to not reached) in AR-V7–negative patients (hazard ra-
tio for clinical or radiographic progression with AR-V7 positivity, 16.5; 95% CI, 3.3 to 82.9; P<0.001 by the log-rank test).
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mained marginally predictive of shorter clinical 
or radiographic progression–free survival (hazard 
ratio for clinical or radiographic progression, 3.0; 
95% CI, 0.9 to 9.6; P = 0.06); the level of full-
length androgen receptor mRNA was also predic-
tive (hazard ratio, 1.7; 95% CI, 1.1 to 2.6), but 
previous abiraterone use was not (hazard ratio, 
2.6; 95% CI, 0.2 to 27.6). Table S3B in the Supple-
mentary Appendix shows the results of the pro-
pensity-score–weighted multivariable model.
Among abiraterone-treated patients, clinical or 
radiographic progression–free survival was short-
er among men with detectable AR-V7 at baseline 
than among those with undetectable AR-V7 
(P<0.001 in a univariate analysis) (Fig. 3D). In a 
multivariable Cox model adjusted for the expres-
sion of full-length androgen receptor mRNA and 
prior enzalutamide use, the detection of AR-V7 
was the only factor that was independently pre-
dictive of shorter clinical or radiographic pro-
gression–free survival (hazard ratio for clinical 
or radiographic progression, 7.6; 95% CI, 1.0 to 
57.6; P = 0.05); the level of full-length androgen 
receptor mRNA (hazard ratio, 1.1; 95% CI, 0.9 to 
1.5) and previous enzalutamide use (hazard ra-
tio, 1.9; 95% CI, 0.4 to 10.0) were not predictive. 
Table S3D in the Supplementary Appendix shows 
the results of the propensity-score–weighted 
multivariable model.
Overall Survival
A preliminary survival analysis was conducted at 
32% maturity in the enzalutamide-treated cohort 
(i.e., after 32% of the patients [10 patients] had 
died) (median follow-up, 8.4 months) and at 16% 
maturity in the abiraterone-treated cohort (i.e., 
after 16% of the patients [5 patients] had died) 
(median follow-up. 9.3 months). Overall survival 
was shorter in men with detectable AR-V7 at 
baseline than among those with undetectable 
AR-V7 both in the enzalutamide cohort (median, 
5.5 months vs. not reached; hazard ratio for 
death, 6.9; 95% CI, 1.7 to 28.1; P = 0.002 by the 
log-rank test) (Fig. S3A in the Supplementary Ap-
pendix) and in the abiraterone cohort (median, 
10.6 months vs. not reached; hazard ratio for 
death, 12.7; 95% CI, 1.3 to 125.3; P = 0.006 by the 
log-rank test) (Fig. S3B in the Supplementary Ap-
pendix). Owing to the small number of events in 
each cohort, multivariable models were not con-
structed.
Combined Analysis
As an exploratory analysis, we evaluated PSA re-
sponses, PSA progression–free survival, clinical 
or radiographic progression–free survival, and 
overall survival in the combined patient popula-
tion of all 62 participants. The effect of AR-V7 
status on these outcomes remained significant 
(Fig. S4 in the Supplementary Appendix).
Conversion from AR-V7–Negative to AR-V7–
positive Status
Of 42 men with undetectable AR-V7 at baseline 
who had at least one follow-up sample available, 
6 patients (4 receiving enzalutamide and 2 receiv-
ing abiraterone) subsequently converted to AR-V7–
positive status during the course of treatment. 
All 16 patients with detectable AR-V7 at baseline 
who had at least one follow-up sample available 
remained AR-V7–positive during treatment. Clin-
ical outcomes for all patients according to AR-V7 
conversion status are summarized in Table S4 in 
the Supplementary Appendix. Changes in levels 
of AR-V7 expression during the course of treat-
ment are summarized in Figure S5 in the Supple-
mentary Appendix.
Tissue-based Analyses
Seven patients consented to additional tissue-based 
studies: five underwent biopsies of metastatic tu-
mors, and two consented to allow research au-
topsies to be performed after their death. Three 
of the seven patients had detectable AR-V7 in cir-
culating tumor cells; these three patients also 
had detectable AR-V7 in metastatic tumor tissue 
according to RNA in situ hybridization analysis 
(Fig. 4). In addition, AR-V7 and full-length an-
drogen receptor were detected at the protein level 
with the use of Western blot analysis in these 
patients (Fig. S7 in the Supplementary Appendix). 
Conversely, none of the four patients with unde-
tectable AR-V7 in circulating tumor cells had de-
tectable AR-V7 in metastatic tissue on RNA in 
situ hybridization, a finding that suggests good 
concordance. Finally, sequencing of the AR tran-
script with the use of RNA sequencing in meta-
static lesions from two AR-V7–positive patients 
(autopsy specimens) did not identify mutations 
in the androgen-receptor gene that could explain 
resistance but did confirm the presence of AR-V7 
splice junctions in both patients (Fig. S9 in the 
Supplementary Appendix).
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Relationship between Full-Length Androgen 
Receptor mRNA and AR-V7
In all patients with detectable AR-V7, full-length 
androgen receptor mRNA was also expressed and 
at higher levels (with one exception) than the lev-
els of AR-V7; increased expression of AR-V7 was 
generally (but not always) coupled with that of 
full-length androgen receptor mRNA (Fig. 1). Al-
though expression of PSA (an indicator of canoni-
cal androgen-receptor signaling) was generally 
suppressed in AR-V7–negative patients during 
treatment with enzalutamide or abiraterone, PSA 
expression did not decrease in post-treatment 
samples of circulating tumor cells from men 
with detectable AR-V7 at baseline (Fig. S8 in the 
Supplementary Appendix). This observation is 
consistent with continued androgen-receptor sig-
naling despite potent inhibition of full-length 
androgen receptor when AR-V7 coexists with 
full-length androgen receptor and contrasts with 
previous findings from a cell-line model of pros-
tate cancer.19
In addition, genomewide comparisons of two 
AR-V7–negative and two AR-V7–positive metastatic 
tumor samples by means of gene-set enrichment 
analysis of RNA sequencing data (Figs. S9 and 
S10 in the Supplementary Appendix) or by means 
of targeted analysis of a set of genes regulated 
by the canonical androgen receptor (Table S5 in 
the Supplementary Appendix) revealed alterations 
consistent with a shift toward AR-V7–driven 
transcription in AR-V7–positive samples. Finally, 
the addition of AR-V7 status to regression mod-
els that included only levels of full-length andro-
gen receptor mRNA resulted in significant im-
provements in model fit across all clinical 
outcomes evaluated, confirming the added value 
of AR-V7 status in predicting outcomes with 
enzalutamide or abiraterone (Table S6 in the 
Supplementary Appendix).
Discussion
Enzalutamide and abiraterone, two new thera-
pies directed at the androgen receptor, represent 
important advances in the management of cas-
tration-resistant prostate cancer.4,7-9 However, a 
proportion of men do not benefit from these 
agents, and a clearer understanding of the mech-
anisms underlying resistance to these drugs 
would facilitate selection of alternative therapies 
(e.g., chemotherapies) for such patients. We 
found that AR-V7 can be detected reliably from 
circulating tumor cells and that detection of AR-
V7 in tumor cells appears to be associated with 
resistance to both enzalutamide and abiraterone. 
This conceptually simple model is biologically 
plausible, because the protein encoded by AR-V7 







Figure 4. Detection of Full-Length Androgen Receptor mRNA and AR-V7  
in Metastatic Prostate-Cancer Tissue.
In situ detection of full-length androgen receptor mRNA and AR-V7 in 
prostate-cancer tumor specimens was performed with the use of RNA in 
situ hybridization analysis. The tumor-tissue specimens shown are a radi-
cal-prostatectomy (RP) specimen that lacks AR-V7 expression from a pa-
tient (not enrolled in this study) who had not received hormonal treat-
ment, an autopsy-derived specimen of a liver metastasis from a patient 
whose circulating tumor cells were shown to express AR-V7 (Autopsy), and 
core-needle biopsy specimens from a patient in whom AR-V7 was not de-
tected (Biopsy 1) and a patient in whom AR-V7 was detected (Biopsy 2) in 
circulating tumor cells. All the tumor specimens show expression of full-
length androgen receptor mRNA. The prostate-cancer cell lines that served 
as positive and negative controls for AR-V7 detection by means of RNA in 
situ hybridization are shown in Figure S6 in the Supplementary Appendix.
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receptor (the direct target of enzalutamide and 
the indirect target of abiraterone) while remain-
ing constitutively active as a transcription factor 
in a ligand-independent manner.13,16
In our study, no AR-V7–positive patient had 
any appreciable clinical benefit from enzalutamide 
or abiraterone therapy. Moreover, although AR-V7 
detection was associated with increased expres-
sion of full-length androgen receptor mRNA, the 
prognostic effect of AR-V7 was maintained after 
adjustment for levels of full-length androgen re-
ceptor mRNA. Finally, although prior treatment 
with abiraterone or enzalutamide was associated 
with AR-V7 positivity, AR-V7 status remained 
prognostic after adjustment for this factor. There-
fore, the current study shows a strong association 
between the presence of AR-V7 and resistance to 
enzalutamide and abiraterone. If this finding is 
substantiated by others, it is possible that AR-V7 
could be used as a biomarker to predict resis-
tance to enzalutamide and abiraterone and to 
facilitate treatment selection. However, our study 
does not prove a causal role for AR-V7 in mediat-
ing resistance to enzalutamide or abiraterone, 
and it remains possible that AR-V7 is a marker 
of more advanced disease or a higher disease 
burden.
Preclinical studies have shown that androgen-
receptor variants are much more common in 
castration-resistant prostate cancer than in hor-
mone-sensitive prostate cancer,13 that they rep-
resent one potential mechanism driving the emer-
gence of the castration-resistant phenotype,10 
and that they may be responsible for the progres-
sion of castration-resistant prostate cancer.14 
Studies involving patients with castration-resis-
tant prostate cancer have shown that androgen-
receptor variants are often expressed in metasta-
ses20,21 and that high levels of these variants in 
metastatic tissue are associated with faster dis-
ease progression and shorter cancer-specific sur-
vival than are low or undetectable levels.13,16,20 
However, all these studies have been retrospective 
in nature, and none have obtained serial specimens 
across time or investigated the clinical signifi-
cance of androgen-receptor variants in patients 
receiving enzalutamide or abiraterone. 
Several studies have shown that although the 
protein isoforms encoded by androgen-receptor 
splice variants are constitutively active, their func-
tion may be dependent on the activity of full-
length androgen receptor.19 Therefore, despite 
the fact that the protein isoforms encoded by 
androgen-receptor splice variants cannot be tar-
geted directly by currently available drugs, it has 
been hypothesized that inhibition of full-length 
androgen receptor by enzalutamide or abirate-
rone could partially reverse resistance mediated 
by androgen-receptor variants. Our clinical data 
do not support this claim, because we did not 
observe any PSA responses in men harboring 
AR-V7 (all of whom also expressed full-length 
androgen receptor mRNA). An alternative treat-
ment approach for AR-V7–positive patients would 
be to design agents targeting the N-terminal 
domain of the androgen receptor,22-24 which 
would theoretically inhibit both full-length andro-
gen receptor and androgen-receptor isoforms 
that lack the ligand-binding domain; such inhibi-
tors are in early stages of drug development.23,24
There are likely to be multiple additional ex-
planations for primary or acquired resistance to 
enzalutamide and abiraterone. For instance, over-
expression of CYP17A1 (or other steroidogenic 
enzymes) leading to increased synthesis of intra-
crine or paracrine androgens has been shown to 
occur in patients receiving these agents.25-28 In 
addition, point mutations affecting the ligand-
binding domain of the androgen receptor have 
been shown to confer agonistic activity to enzalu-
tamide.29,30 Furthermore, expression of androgen-
regulated genes may be driven by alternative 
steroid receptors, such as the glucocorticoid re-
ceptor.31,32 Finally, inhibition of the androgen 
receptor may lead to reciprocal up-regulation of 
other oncogenic pathways, such as the PI3K–
AKT pathway.33 It is unlikely that all cases of 
enzalutamide or abiraterone resistance will be 
explained by a single cause.
In conclusion, our data support an association 
between AR-V7 and resistance to both enzalu-
tamide and abiraterone in patients with castra-
tion-resistant prostate cancer. These findings re-
quire large-scale prospective validation.
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